Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic Acid, in rats and humans.

Battelle Pacific Northwest Division, Richland, Washington 99352, USA.
Toxicological Sciences (Impact Factor: 3.85). 06/2005; 85(1):476-90. DOI: 10.1093/toxsci/kfi119
Source: PubMed


An extensive database on the toxicity and modes of action of ethylene glycol (EG) has been developed over the past several decades. Although renal toxicity has long been recognized as a potential outcome, in recent years developmental toxicity, an effect observed only in rats and mice, has become the subject of extensive research and regulatory reviews to establish guidelines for human exposures. The developmental toxicity of EG has been attributed to the intermediate metabolite, glycolic acid (GA), which can become a major metabolite when EG is administered to rats and mice at high doses and dose rates. Therefore, a physiologically based pharmacokinetic (PBPK) model was developed to integrate the extensive mode of action and pharmacokinetic data on EG and GA for use in developmental risk assessments. The resulting PBPK model includes inhalation, oral, dermal, intravenous, and subcutaneous routes of administration. Metabolism of EG and GA were described in the liver with elimination via the kidneys. Metabolic rate constants and partition coefficients for EG and GA were estimated from in vitro studies. Other biochemical constants were optimized from appropriate in vivo pharmacokinetic studies. Several controlled rat and human metabolism studies were used to validate the resulting PBPK model. When internal dose surrogates were compared in rats and humans over a broad range of exposures, it was concluded that humans are unlikely to achieve blood levels of GA that have been associated with developmental toxicity in rats following occupational or environmental exposures.

Download full-text


Available from: Ed Carney, Jan 11, 2014
  • Source
    • "This happens because of several physicochemical conditions, such as supersaturation, nucleation, growth aggregation, and retention in the renal tubular system. This experimental condition affects the normal renal function (Bashir and Gilani, 2009; Corley et al., 2005; Liao and Richardson, 1972). Also, the classical pathologic finding is the acute tubular necrosis of proximal tubular cells and the presence of calcium oxalate crystals in the proximal tubules. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to determine whether hypothyroidism protects against ethylene glycol (EG)-induced renal damage and whether the redox environment participates in the protection process. We used 36 male Wistar rats divided into four groups: (1) euthyroid, (2) euthyroid + 0.75% EG, (3) hypothyroid, and (4) hypothyroid + 0.75% EG. Hypothyroidism occurred 2 weeks after thyroidectomy. The parathyroid gland was reimplanted. EG was administrated for 21 days in drinking water. On day 21, the renal function was assessed and then the rats were decapitated. The left kidney was processed for histology, and the right kidney was used to determine the redox environment, oxidative stress, and the testing of the antioxidant enzymatic system. EG in euthyroid rats reduced the hydric and electrolytic balance and it also caused oxidative stress and renal damage. Hypothyroidism per se modifies the renal function causing a low osmolal and potassium clearance and the filtered load of potassium and sodium. In addition, there was an enhanced redox state because hypothyroidism increases the reduced glutathione concentration caused by a high activity of γ-glutamylcysteine synthase. Hypothyroidism is a protective state against EG because the changes in the renal function were smaller than in the euthyroid state. The oxidative stress and cellular damage were ameliorated by the hypothyroid condition. Also, the hypothyroidism-enhanced redox environment protects against EG-induced oxidative stress, renal damage, and renal dysfunction.
    Toxicology and Industrial Health 04/2012; 29(6). DOI:10.1177/0748233712442710 · 1.86 Impact Factor
  • Source
    • "where f u is the unbound fraction of BMP in blood, fu inc is the fraction of BMP unbound to microsomal protein, and CL int is the total in vitro intrinsic clearance (Houston, 1994). The rat hepatic blood flow (Q) was assumed to be 45 ml/min/kg (Corley et al., 2005), and f u was determined to be 0.6 by a method described previously by Cheng et al. (2009). fu inc was estimated to be 0.94 (Hallifax and Houston, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: 2,2-Bis(bromomethyl)-1,3-propanediol (BMP) is a brominated flame retardant used in unsaturated polyester resins. In a 2-year bioassay BMP was shown to be a multisite carcinogen in rats and mice. Because glucuronidation is the key metabolic transformation of BMP by rats, in this study the in vitro hepatic glucuronidation of BMP was compared across several species. In addition, the glucuronidation activities of human intestinal microsomes and specific human hepatic UDP-glucuronosyltransferase (UGT) enzymes for BMP were determined. To explore other possible routes of metabolism for BMP, studies were conducted with rat and human hepatocytes. Incubation of hepatic microsomes with BMP in the presence of UDP-glucuronic acid resulted in the formation of a BMP monoglucuronide. The order of hepatic microsomal glucuronidation activity of BMP was rats, mice > hamsters > monkeys > humans. The rate of glucuronidation by rat hepatic microsomes was 90-fold greater than that of human hepatic microsomes. Human intestinal microsomes converted BMP to BMP glucuronide at a rate even lower than that of human hepatic microsomes. Among the human UGT enzymes tested, only UGT2B7 had detectable glucuronidation activity for BMP. BMP monoglucuronide was the only metabolite formed when BMP was incubated with suspensions of freshly isolated hepatocytes from male F-344 rats or with cryopreserved human hepatocytes. Glucuronidation of BMP in human hepatocytes was extremely low. Overall, the results support in vivo studies in rats in which BMP glucuronide was the only metabolite found. The poor glucuronidation capacity of humans for BMP suggests that the pharmacokinetic profile of BMP in humans will be dramatically different from that of rodents.
    Drug metabolism and disposition: the biological fate of chemicals 03/2010; 38(6):957-62. DOI:10.1124/dmd.110.032110 · 3.25 Impact Factor
  • Source
    • "The extent of absorption was increased when applied in a DMF-H 2 O, a more hydrophobic vehicle. The blood clearance for Bmim-Cl, NBuPy-Cl, and BmPy-Cl exceeds published values for the glomerular filtration rate (0.5–1.2 ml/min/100-g rat) (Corley et al., 2005), suggesting a secretory mechanism for these ILs. Secretion is mediated by a variety of transporters, many of which are known to be critical in the elimination of a variety of clinically used drugs (Jonker and Schinkel, 2004) as well as occupationally and environmentally relevant compounds (Prasad et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies were conducted to characterize the effects of dose and route of administration on the disposition of 1-butyl-1-methylpyrrolidinium (BmPy-Cl) in male Fischer-344 rats. After a single oral administration of [(14)C]BmPy-Cl (50 mg/kg), BmPy-Cl in the blood decreased rapidly after C(max) of 89.1 min with a distribution half-life (t(1/2)(alpha)) of 21 min, an elimination half-life (t(1/2)(beta)) of 5.6 h, and a total body clearance of 7.6 ml/min. After oral administration (50, 5, and 0.5 mg/kg), 50 to 70% of the administered radioactivity was recovered in the feces, with the remainder recovered in the urine. Serial daily oral administrations of [(14)C]BmPy-Cl (50 mg/kg/day for 5 days) did not result in a notable alteration in disposition or elimination. After each administration, 88 to 94% of the dose was eliminated in a 24-h period, with 63 to 76% of dose recovered in the feces. Intravenous administration of [(14)C]BmPy-Cl (5 mg/kg) resulted in biphasic elimination. Oral systemic bioavailability was 43.4%, approximately equal to the dose recovered in urine after oral administration (29-38%). Total dermal absorption of [(14)C]BmPy-Cl (5 mg/kg) was moderate when it was applied in dimethylformamide-water (34 + or - 13%), variable in water (22 + or - 8%), or minimal in ethanol-water (13 + or - 1%) vehicles. Urine was the predominant route of elimination regardless of vehicle. Only parent [(14)C]BmPy-Cl was detected in the urine after all doses and routes of administration. BmPy-Cl was found to be a substrate for (K(t) = 37 microM) and inhibitor of (IC(50/tetraethylammonium) = 0.5 microM) human organic cation transporter 2. In summary, BmPy-Cl is moderately absorbed, extracted by the kidney, and eliminated in the urine as parent compound, independent of dose, number, or route of administration.
    Drug metabolism and disposition: the biological fate of chemicals 09/2009; 37(11):2171-7. DOI:10.1124/dmd.109.029082 · 3.25 Impact Factor
Show more